Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

2.

The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue.

Odgren PR, Kim N, MacKay CA, Mason-Savas A, Choi Y, Marks SC Jr.

Connect Tissue Res. 2003;44 Suppl 1:264-71.

PMID:
12952207
3.

Evidence that the rat osteopetrotic mutation toothless (tl) is not in the TNFSF11 (TRANCE, RANKL, ODF, OPGL) gene.

Odgren PR, Kim N, van Wesenbeeck L, MacKay C, Mason-Savas A, Safadi FF, Popoff SN, Lengner C, van-Hul W, Choi Y, Marks SC Jr.

Int J Dev Biol. 2001 Dec;45(8):853-9.

4.

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function.

Wong BR, Josien R, Choi Y.

J Leukoc Biol. 1999 Jun;65(6):715-24. Review.

5.

Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis.

Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y.

J Exp Med. 2005 Sep 5;202(5):589-95.

6.

Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation.

Lee J, Kim K, Kim JH, Jin HM, Choi HK, Lee SH, Kook H, Kim KK, Yokota Y, Lee SY, Choi Y, Kim N.

Blood. 2006 Apr 1;107(7):2686-93. Epub 2005 Dec 1.

7.

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.

Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM.

Nature. 1999 Jan 28;397(6717):315-23.

PMID:
9950424
8.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

9.

Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T.

J Biol Chem. 2003 Jun 27;278(26):23971-7. Epub 2003 Apr 15.

10.
11.

Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.

Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R.

J Biol Chem. 2004 Feb 27;279(9):8269-77. Epub 2003 Dec 15.

13.

Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis.

Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N.

J Biol Chem. 2005 Oct 21;280(42):35209-16. Epub 2005 Aug 18.

14.
15.

Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE.

Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Castellanos Y, Rho J, Wong BR, Josien R, Kim N, Rennert PD, Choi Y.

J Exp Med. 2000 Nov 20;192(10):1467-78.

16.

TRANCE together with IL-7 induces pre-B cells to proliferate.

Kato I, Sato H, Kudo A.

Eur J Immunol. 2003 Feb;33(2):334-41.

17.

The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection.

Guillonneau C, Louvet C, Renaudin K, Heslan JM, Heslan M, Tesson L, Vignes C, Guillot C, Choi Y, Turka LA, Cuturi MC, Anegon I, Josien R.

J Immunol. 2004 Feb 1;172(3):1619-29.

18.

TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype.

Fox SW, Fuller K, Bayley KE, Lean JM, Chambers TJ.

J Immunol. 2000 Nov 1;165(9):4957-63.

19.

Biology of the TRANCE axis.

Walsh MC, Choi Y.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):251-63. Review.

PMID:
12787563
20.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk